Anti-beta-stimulant single-chain antibody and application thereof

By developing single-chain antibodies against β-stimulant, using diazon method and PCR technology, the cumbersome and poor stability of existing detection methods are solved, and the rapid and efficient detection of β-stimulant is achieved, providing high sensitivity and stability detection solutions.

CN118909131AActive Publication Date: 2024-11-08XINXIANG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410999211.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

The existing β-doping detection methods have problems such as cumbersome procedures, expensive, time-consuming and poor stability. In particular, the preparation methods of monoclonal antibodies are complex and unoptimized, resulting in poor stability of immunologic detection.

Method used

A single-chain antibody with anti-β-stimulant was developed, coupled to carrier proteins through the diazon method, and amplified by PCR technology to obtain highly sensitive anti-brombutor and anti-zipaterol single-chain antibody, which binds to phage display. Technology to establish rapid detection methods.

Benefits of technology

It realizes rapid and sensitive detection of β-stimulants, reduces detection cost and time, improves the stability and reliability of detection results, and provides efficient detection tools.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909131A_ABST
    Figure CN118909131A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-beta-stimulant single-chain antibody and application thereof, and belongs to the technical field of biology. The beta-stimulant is brombuterol, the anti-brombuterol single-chain antibody is composed of a heavy chain variable region, a connecting peptide and a light chain variable region, the connecting peptide is located between the heavy chain variable region and the light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.2. The method comprises the following steps: coupling BRO small molecules and ZIL small molecules with bovine serum albumin and chicken serum albumin, and screening to obtain a high-sensitivity mAb cell strain capable of secreting specificity; then, on the basis of the obtained monoclonal cell strain, a complete antibody gene is obtained through PCR technology amplification, finally, a high-sensitivity and high-specificity single-chain antibody is obtained through screening, and a foundation is laid for follow-up development of BRO and ZIL rapid detection kits.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an anti-β-stimulant single-chain antibody and application thereof. Background Art

[0002] Brombuterol (BRO) and Zilpaterol (ZIL) are both types of "lean meat enhancers" and are β-stimulants. They can significantly increase the lean meat rate of animals and easily form residues in the edible tissues of animals. Excessive use can cause symptoms such as shortness of breath and muscle tremors, posing a serious threat to the safety of animal-derived food.

[0003] At present, the detection of β-stimulants is still mainly based on instrumental analysis, including gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry. Although these methods can accurately detect BRO and ZIL in different samples quantitatively and qualitatively, the widespread use of this detection method is greatly limited because the instruments are expensive, time-consuming, and labor-intensive, and require dedicated laboratories and operators, as well as lengthy and strict sample processing procedures. The antibodies used in the immunological detection methods for BRO and ZIL are mainly monoclonal antibodies (monoclonal antibodies, mAb) and polyclonal antibodies (polyclonal antibodies, pAb). The conventional preparation methods of mAb and pAb have the disadvantages of cumbersome and complex preparation procedures, long time, and non-optimization, and differences in antibody sensitivity between different batches, which easily lead to poor stability of the constructed immunological detection methods. Compared with traditional antibodies, single-chain antibodies (ScFv) are genetically engineered antibodies with only one chain. They can not only be studied at the molecular level, but also the affinity and stability of antibodies can be improved through modification techniques such as random mutagenesis and site-directed mutagenesis. Based on the combination of phage display technology, the acquisition of this antibody can be mass-produced without preparing hybridoma cell lines. It has the advantages of convenience and easy preparation, and has gradually become an important research object for establishing rapid immunological detection methods. Summary of the invention

[0004] In order to solve the above technical problems, the purpose of the present invention is to provide an anti-β-stimulant single-chain antibody and its application to solve the problems of cumbersome procedures, high prices, time-consuming and labor-intensive or poor stability in the existing detection of β-stimulants.

[0005] The technical solution of the present invention to solve the above technical problems is as follows:

[0006] A single-chain antibody against beta-agonists, wherein the beta-agonist is bromobuterol. The single-chain antibody against bromobuterol consists of a heavy chain variable region, a connecting peptide and a light chain variable region, wherein the connecting peptide is located between the heavy chain variable region and the light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2.

[0007] Furthermore, the nucleotide sequence encoding the heavy chain variable region of the anti-bromobuterol single-chain antibody is shown in SEQ ID NO.3, and the nucleotide sequence encoding the light chain variable region is shown in SEQ ID NO.4.

[0008] Furthermore, the amino acid sequence of the connecting peptide is shown in SEQ ID NO.5.

[0009] Furthermore, the β-agonist is zilpaterol, and the anti-zilpaterol single-chain antibody consists of a heavy chain variable region, a connecting peptide and a light chain variable region, the connecting peptide is located between the heavy chain variable region and the light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.6, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.7.

[0010] Furthermore, the nucleotide sequence encoding the heavy chain variable region of the anti-zilpaterol single-chain antibody is shown in SEQ ID NO.8, and the nucleotide sequence encoding the light chain variable region is shown in SEQ ID NO.9.

[0011] Furthermore, the amino acid sequence of the connecting peptide is shown in SEQ ID NO.10.

[0012] An expression vector, bacteriophage or recombinant bacterium, comprising all the above nucleotides.

[0013] A monoclonal cell line comprising all of the above nucleotides.

[0014] A kit for detecting beta-agonists, comprising the above-mentioned single-chain antibody against beta-agonists.

[0015] The use of the above-mentioned anti-β-agonist single-chain antibody or the kit for detecting β-agonist in the detection of β-agonist.

[0016] The present invention has the following beneficial effects:

[0017] The present invention couples BRO and modified ZIL small molecules with bovine serum albumin and chicken serum albumin respectively by using the diazo method, immunizes mice with the prepared complete antigens, and identifies the serum titer and sensitivity, thereby screening and obtaining a cell strain capable of secreting specific and highly sensitive mAbs; then, based on the obtained monoclonal cell strains, PCR technology is used to amplify complete antibody genes, and finally highly sensitive anti-bromobuterol single-chain antibodies and anti-zilpaterol single-chain antibodies are screened and obtained, thereby laying a foundation for the subsequent development of rapid detection kits for BRO and ZIL. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is the BSA protein standard curve in Example 1;

[0019] Figure 2 The SDS-PAGE identification results of BRO-BSA and BRO-OVA in Example 1, wherein M in A is rainbow maker 180, 1 is the BRO-BSA coupling product, and 2 is the BSA carrier protein; M in B is rainbow maker 180, 1 is the OVA carrier protein, and 2 is the BRO-OVA coupling product;

[0020] Figure 3 The UV scanning images of BRO-OVA and BRO-BSA in Example 1, wherein A is BRO-OVA and B is BRO-BSA;

[0021] Figure 4 The mouse serum titer result of BRO-BSA in Example 1;

[0022] Figure 5 is the IC of the BRO mouse polyclonal antiserum in Example 1 50 Measurement results;

[0023] Figure 6 This is a microscope photo of the feeder layer cells in Example 2;

[0024] Figure 7 These are microscope photos of the growth status of fused cells in Example 2, wherein A is the third day, B is the fourth day, C is the sixth day, D is the seventh day, E is the tenth day, and F is the thirteenth day;

[0025] Figure 8 The inhibition rate test result of the cell fusion positive wells in Example 2;

[0026] Fig. 9 The results of the 1st to 3rd limiting dilution positive empty inhibition rate tests in Example 2, wherein A is the first time, B is the second time, and C is the third time;

[0027] Fig.10is the titer and IC of the 2B10 cell supernatant in Example 2 50 Measurement results;

[0028] Fig.11 is the titer and IC of mouse ascites in Example 2 50 Measurement results;

[0029] Fig.12 This is the electrophoresis diagram of total RNA extracted from 2B10 cells in Example 3;

[0030] Fig.13 The electrophoresis diagram of the VH gene and VL gene fragments in Example 3, wherein M is DL200 DNA Ladder, 1 and 2 are VH genes, and 3 and 4 are VL genes;

[0031] Fig.14 This is the electrophoresis diagram of the ScFv connection in Example 3;

[0032] Fig.15 The electrophoresis diagram of the pCANTAB-5E phagemid vector in Example 3;

[0033] Fig.16 The positive bacterial solution PCR identification results in Example 3;

[0034] Fig.17 The phage-ELISA test results of BRO phage in Example 3;

[0035] Fig.18 The Western Blotting results of BRO-ScFv in the periplasm in Example 3. Wherein, M is Rainbow Maker 180, 1 is BRO-ScFv in the periplasm, and 2 is the supernatant of the induced expression bacteria;

[0036] Fig.19 The titer identification results and antibody affinity identification results of the BRO-ScFv single-chain antibody in Example 3, wherein the upper figure is the titer identification result, and the lower figure is the affinity identification result;

[0037] Fig. 20 The SDS-PAGE identification result of ZIL-OVA in Example 4, wherein M is Rainbow Maker 180, 1 is OVA carrier protein, and 2 is ZIL-OVA coupling product;

[0038] Fig.21 The SDS-PAGE identification result of ZIL-BSA in Example 4, wherein M is Rainbow Maker 180, 1 is BSA carrier protein, and 2 is ZIL-BSA coupling product;

[0039] Fig. 22It is the UV scanning image of ZIL-OVA and ZIL-BSA in Example 4;

[0040] Fig.23 The results of indirect ELISA testing of mouse polyclonal antibody titer in Example 4;

[0041] Fig.24 This is a graph showing the titer detection of mouse ascites after immunization with hybridoma cell 5E7-9A in Example 6;

[0042] Fig.25 The sensitivity standard curve of mouse ascites in Example 6;

[0043] Fig.26 This is the indirect ELISA standard curve of the ZIL single-chain antibody in Example 6. DETAILED DESCRIPTION

[0044] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0045] Example 1: Synthesis and identification of complete BRO antigen

[0046] 1. Modification of BRO molecules

[0047] (1) Diazotization process of BRO

[0048] Use a high-precision balance to accurately weigh 3 mg of BRO sample and dissolve it in 1.5 mL of 0.1 mol hydrochloric acid solution that has been pre-cooled. In an ice-water bath, add 680 μL of 1 mg / mL sodium nitrite solution that has been pre-cooled to low temperature step by step while stirring at a low speed. Use starch-KI test paper to detect whether sodium nitrite is excessive. The judgment standard is that the test paper turns gray-purple. The entire diazotization process needs to be stirred continuously in a 4°C refrigerator under light-proof conditions for 1 to 2 hours.

[0049] (2) Conjugation of BRO diazonium salt with two carrier proteins (BSA and OVA)

[0050] Use a precision balance to accurately weigh 26 mg BSA and 18.4 mg OVA to ensure a constant molar ratio of 20:1 between BRO and the carrier protein. Dissolve BSA and OVA in 3 mL 0.1 mol / L sodium borate solution (pH 8.6). Stir the mixture in an ice bath for 2 h. Subsequently, divide the BRO diazonium salt solution obtained in the first step into two equal parts. Slowly add each part dropwise to the solution containing BSA and OVA. During this process, it is necessary to use a diluted sodium hydroxide solution to adjust the pH value of the mixture in time to ensure that it is stable at 8.0, and then continue to stir at low temperature and let it stand overnight to promote the coupling reaction to proceed fully. The BRO molecular modification flow chart is shown below:

[0051]

[0052] (3) Purification dialysis

[0053] After the reaction was completed on the second day, the bright yellow reaction product was collected and dialyzed with phosphate buffered saline (PBS) at 4°C for 3 consecutive days, during which the dialysate needed to be replaced.

[0054] (4) Concentration determination and storage

[0055] The protein concentration of the coupled product was determined using the Bradford protein quantification kit from Solebo. After obtaining an accurate concentration reading, the sample was appropriately diluted to a concentration of 1 mg / mL. Subsequently, the sample was divided into 1.5 mL EP tubes and stored in a -80°C freezer.

[0056] 2. Identification of BRO complete antigen

[0057] (1) Identification of complete antigen concentration

[0058] The concentration of complete antigen was determined using the Bradford method. The steps are as follows:

[0059] Take 10 μL of 5 mg / mL BSA standard, add 240 μL PBS and mix well to prepare a 0.2 mg / mL standard solution.

[0060] Thoroughly mix 5×G250 staining reagent and sterile double distilled water to dilute into 1×G250 staining solution.

[0061] In a 96-well ELISA plate, the above standard solution was added to each well in different volumes (0-20 μL), and then supplemented with PBS diluent to a total volume of 20 μL.

[0062] The complete antigen sample was diluted 2-256 times, and 20 μL of each dilution was added to a 96-well plate. 200 μL of 1×G250 staining solution was added to each well and allowed to stand for 3 minutes. The absorbance was measured at a wavelength of 595 nm using a spectrophotometer. The data was recorded, and a graph of the absorbance and concentration was drawn based on the standard curve. The protein concentration of the complete antigen sample to be tested was calculated by comparison.

[0063] The experimental results are as follows Figure 1 As shown in the figure, by measuring the absorbance value of BSA protein standard at a wavelength of 595nm, a standard curve of BSA protein was successfully constructed. The protein concentration of the immune antigen BRO-BSA was calculated to be 1.4mg / mL using the standard curve, and the protein concentration of the detection antigen BRO-OVA was 2mg / mL.

[0064] (2) SDS-PAGE identification of complete antigen

[0065] Sample treatment: Adjust the concentration of BRO-BSA, BSA, BRO-OVA and OVA to 4 μg / mL, mix with loading buffer, boil in boiling water for 10 minutes for denaturation treatment, set the voltage to 80V during electrophoresis, increase it to 120V after the sample enters the separation gel, and run to the bottom of the gel to complete the electrophoresis. Stain the gel after electrophoresis with Coomassie Brilliant Blue for 45 minutes, and recover the dye solution. Decolorize and replace the decolorizing solution every 2 hours until the gel is completely transparent. Take pictures with a UV gel imaging system and analyze the results.

[0066] The experimental results are as follows Figure 2 As shown. The prepared coupled proteins: BRO-BSA and BRO-OVA were identified by electrophoresis. The experimental results showed that the migration speed of the complete antigens BRO-BSA and BRO-OVA after the coupling reaction was significantly lower than that of their respective carrier proteins BSA and OVA. This reduction in migration speed is due to the relative increase in the molecular weight of BRO-BSA and BRO-OVA after coupling, which leads to more hindrance to migration in the gel. This phenomenon confirms that the BRO molecules have been effectively coupled with the BSA and OVA carrier proteins to form the expected coupled protein products.

[0067] (3) UV full wavelength identification of complete antigen

[0068] Use PBS to adjust the concentrations of BSA, OVA and BRO standard solutions, BRO-BSA and BRO-OVA to 1 mg / mL. Use an ELISA reader to perform UV full wavelength scanning identification on the complete antigen. After calibrating with PBS as the baseline, measure the absorbance of each sample in the range of 200nm to 500nm, and use origin 2021 software to make a spectrum. By analyzing whether the absorption peak of the sample has peak shift, it is possible to evaluate whether the synthesis of the BRO complete antigen is successful.

[0069] The experimental results are as follows Figure 3 As shown. There is an obvious peak shift between the maximum absorption peak wavelength of the complete antigen coupling product and the carrier protein alone. The results confirm from another perspective that BRO has successfully undergone an effective coupling reaction with the carrier protein. The introduction of new chemical groups has changed the spectral characteristics of the complete antigen, resulting in a shift in the maximum absorption peak wavelength in the ultraviolet spectrum. Therefore, through the analysis of ultraviolet scanning technology, it can be confirmed that the coupling reaction between BRO and the carrier protein has been successfully carried out, generating a complete antigen that meets the expected characteristics.

[0070] 3. Animal Immunization

[0071] The purchased 7-week-old BALB / c female mice were divided into two groups and given the first immunization after one week of adaptive feeding. BRO-BSA was used as the immunogen, mixed with FCA in equal volumes, and an emulsifier was prepared at a dose of 200 μL / mouse, and finally a stable oil-in-water emulsion was formed in water. According to this method, FIA was used for booster immunization every two weeks, and five immunizations were performed in succession. The detailed immunization scheme is shown in Table 1.

[0072] Table 1 BRO-BSA immunization program

[0073]

[0074] (1) Determination of mouse antibody serum titer by indirect ELISA

[0075] Blood collection: After stunning the mouse, cut the tail and collect 2 μL of blood, which was dissolved in 198 μL PBS, i.e. diluted 1:100.

[0076] Coating: 5 μg / mL BRO-OVA was coated in a 96-well plate, 50 μL / well, overnight at 4°C, washed 5 times with PBST, and patted dry;

[0077] Blocking: Add 200 μL of 5% skim milk powder to each well for blocking, 37°C, 2 h, wash 5 times with PBST, and pat dry;

[0078] Add primary antibody: add 50 μL PBS to each well, then add the above 1:100 diluted mouse serum, pipette to mix, move to the next well, pipette to mix again, and so on, dilute the mouse serum in multiples (1:200-1:25600), incubate at 37°C for 1 hour, wash with PBST 5 times, and use non-immunized mouse serum as a negative control;

[0079] Add secondary antibody: dilute HRP-goat anti-mouse IgG to 1:5000 with blocking solution, 50 μL / well, incubate at 37°C for 40 min, wash 5 times with PBST, and pat dry;

[0080] TMB color development: use TMB color development solution 50 μL / well, 37°C, 10 min;

[0081] Add stop solution: Add 50 μL / well of H2SO4 stop solution to the 96-well plate to stop the reaction;

[0082] Read and record the results: Use an ELISA reader to measure the OD of the 96-well plate 450 The value is set, the sample well is set as P, the negative control well is set as N, and the maximum dilution factor of the serum when P / N ≥ 2.1 is determined as the titer of the mouse antibody.

[0083] The experimental results are as follows Figure 4 As shown. Six BALB / c mice were divided into two groups, A and B (named A1, A2, A3, B1, B2, and B3, respectively). All six mice immunized with BRO-BSA successfully produced antibodies against BRO. According to the judgment criteria set in the experiment, that is, the P / N value was greater than 2.1, compared with the serum of negative mice without immunization, the titer of pAb in the serum of immunized mice was significantly increased, reaching 1:1.28×10 4 This result indicates that the conjugated immunogen BRO-BSA can effectively induce specific antibody responses in mice.

[0084] (2) icELISA determination of mouse serum sensitivity

[0085] Serum collection, coating and blocking were performed by the method described in (1).

[0086] Add standard and serum: Add different concentrations of BRO standard solution (500ng~0.5ng) to the 96-well plate, add 50μL PBS to the last well as blank control, and use the titer to detect the OD 450 The titer with a value close to 1 was diluted as the working concentration, and 25 μL of mouse polyclonal antiserum was added to each well, washed five times with PBST, and patted dry;

[0087] Add secondary antibody: 1:5000 HRP-goat anti-mouse IgG, 50 μL / well, 37°C, 40 min, wash 5 times with PBST, and pat dry;

[0088] TMB color development: add 50 μL TMB color development solution to each well, 37°C, 10 min;

[0089] Add stop solution: Add 50 μL / well of H2SO4 to the 96-well plate to stop the reaction;

[0090] Read and analyze the results: Measure the OD of each well using a microplate reader 450 The data were processed and analyzed using Origin 2021 software, with the concentration of BRO standard as the horizontal axis and B / B0 (B: absorbance value of BRO standard; B0: absorbance value without BRO standard) as the vertical axis. The curve was fitted using the Logistics5 function equation. From the obtained curve, its IC 50 value.

[0091] The experimental results are as follows Figure 5 The IC of B1 mouse serum was calculated as 50 The lowest value was 25.28 ng / mL.

[0092] Example 2: Screening and identification of anti-BRO hybridoma cell lines

[0093] 1. Preparation of anti-BRO mAb

[0094] (1) Cultivation of SP2 / 0 cells

[0095] The SP2 / 0 cells were cultured in a cell culture flask in a constant temperature incubator, and were passaged when the cell density reached about 80%.

[0096] (2) Enhanced immunization of mice

[0097] The optimal IC for immune response in Example 1 50 Three days before cell fusion, 100 μg of immunogen was mixed with 100 μL PBS and injected directly into the mouse's peritoneum. No adjuvant was used in the booster immunization.

[0098] (3) Preparation of feeder layer

[0099] Unimmunized BALB / c mice were selected and killed by dislocating the neck using forceps, and then immediately immersed in 75% alcohol (mass fraction) for disinfection and fixed on a sterile wax tray. The whole body of the mouse, especially the neck and abdomen, was thoroughly and carefully wiped and disinfected to achieve a sterile state.

[0100] After disinfection and drying, use autoclaved surgical scissors and tweezers to cut the epidermis to the right of the midline of the mouse abdomen under aseptic operation to expose the peritoneal membrane. Pay special attention not to touch or puncture the intestine during the operation to prevent contamination of the intestinal contents. Next, slowly inject the HAT culture medium that has been pre-cooled to an appropriate temperature into the mouse's abdominal cavity through a 5mL syringe, while ensuring that the needle tip is away from the intestinal tissue. After injecting the culture medium, use an alcohol cotton ball to gently pat the mouse's abdomen to encourage the macrophages in the abdominal cavity to detach from the peritoneum as much as possible and integrate into the culture medium. Subsequently, through the same needle insertion path, slowly draw out the peritoneal fluid mixed with macrophages, merge it into the pre-prepared HAT culture medium, and use a pipette to gently blow and mix to ensure that the cells are evenly distributed.

[0101] Next, macrophages were distributed to a 96-well cell culture plate, with 100 μL added to each well. The culture plate filled with cells was placed in a constant temperature and humidity incubator at 37° C. and 5% CO 2 (volume fraction) for overnight culture.

[0102] On the second day, carefully observe the cells in each well under a microscope and check the color of the culture medium to see if there are signs of microbial contamination. At the same time, evaluate the growth status of the feeder layer cells, including the cell adhesion, morphology, and activity, to ensure that the quality of the feeder layer cells meets the needs of subsequent experiments. Figure 6 shown.

[0103] (3) Cell fusion

[0104] Select 8 bottles of SP2 / 0 cells from the cell culture bottles with round and transparent growth. Rinse the cells with preheated GNK solution to ensure that cell debris and a few cells in poor condition are removed to improve fusion efficiency.

[0105] Blood was collected from the orbits of B1 mice and placed at -80°C for subsequent use as positive blood. The mice were killed by dislocating the neck and immersed in 75% alcohol (mass fraction), and then moved into an ultra-clean workbench. The mice were fixed in a fully disinfected wax tray and the whole body of the mice was disinfected. Using sterile scissors and tweezers, remove the spleen of the mouse and place it in a high-pressure beaker with a nylon mesh. Rinse the spleen with GNK solution, then use scissors and tweezers to cut the spleen into pieces, and finally rinse the spleen cells with 40 mL of GNK solution and collect them in a centrifuge tube, centrifuge at 1000 r / min for 10 minutes, and discard the supernatant.

[0106] The SP2 / 0 cells prepared in the above step were mixed with spleen cells in a centrifuge tube, and the cells were centrifuged at 1000 r / min for 5 min to retain the cell pellet. The cell clumps were gently shaken to break up.

[0107] In a clean bench, add 1 mL of PEG 1500 to the mixed cell mass within 60 seconds. Then, add 15 mL of preheated GNK solution to the centrifuge tube within 80 seconds, and finally add 40 mL of GNK solution to the centrifuge tube, and then incubate in a 42°C water bath for 5 minutes. Centrifuge at 1000 r / min for 5 minutes, retain the cell pellet, and gently break up the cell mass.

[0108] Slowly add 40 mL of HAT medium to the cell pellet, gently pipette to mix, and then transfer to a plate. Add 40 mL of HAT medium again and add 100 μL to each well. Add a total of 8 96-well plates and then culture in a 37°C incubator.

[0109] (4) Screening of positive hybridoma cells

[0110] In order to ensure that the fused cells maintain a relatively stable growth state in the early stage and avoid a decrease in cell viability due to excessive interference, the cells in the 96-well plate were not observed within the first 3 days after inoculation. By the 3rd day, under microscopic observation, the cells had aggregated to form small cell clusters of 2 to 5 cells. By the 5th and 10th days, as the cell clusters continue to proliferate and expand, if the culture medium is observed to turn yellow, indicating the accumulation of metabolites, half of the medium needs to be replaced. By the 13th day, it is expected that the hybridoma cell clusters will occupy 40% to 70% of the culture well area (such as 40% to 70% of the culture well area). Figure 7 At this time, in addition to changing the medium half-volume again, indirect ELISA and icELISA tests are performed simultaneously to evaluate the titer and sensitivity of the antibodies in the hybridoma cell supernatant, and positive cell clones with high titer and high sensitivity are screened out accordingly. With multiple half-volume changes and subsequent limiting dilutions, the original HT medium and HAT medium can be gradually replaced with 1640 medium.

[0111] Determination of OD of supernatant by icELISA 450 The experimental results are as follows Figure 8 As shown, 13 positive clone wells were obtained. Well 5C3 had an inhibition rate of 57.0% at a BRO concentration of 50 ng / mL, so it was selected as the positive well for subcloning.

[0112] (5) Limiting dilution of positive cell wells

[0113] Live cell counting: Trypan blue staining was used to identify cell viability, the number of live cells was counted under a microscope, and the cell concentration was determined based on the calculation formula.

[0114] Feeder layer preparation: Prepare feeder cells one day before performing limiting dilution to ensure that their density is appropriate and sufficient to support the proliferation of hybridoma cells.

[0115] Cell dilution step: Take 1000 cells from dilution I and add them to 5 mL of culture medium, and mix thoroughly by pipetting. Take 1.1 mL of cell suspension from dilution I and add it to 9.9 mL of fresh culture medium, and mix again by pipetting, which is recorded as dilution II. Further dilution is divided into two conditions, A and B. Take 3 mL of cell suspension from dilution II and add it to 7 mL of new culture medium, and mix thoroughly, which is recorded as dilution Ш.

[0116] Cell seeding layout: In dilution I, 100 μL of cell suspension is seeded into each well, covering half of the 96-well plate, and each well is expected to contain about 20 cells. In dilution II, 100 μL is seeded into each well, covering half of the plate, and each well is expected to contain 2 cells. Similarly, the wells of dilution Ш are still seeded with 100 μL. Due to the higher dilution, two plates are required, and theoretically each well contains about 0.6 cells.

[0117] Limiting dilution screening and amplification: Usually three rounds of subclone screening are performed. For monoclonal cells with stable titer and excellent sensitivity, they are gradually transferred to 24-well plates and 6-well plates for culture, and finally large-scale amplification is performed in T25 cell culture flasks. The screened cell lines are frozen and stored in liquid nitrogen tanks for subsequent experiments.

[0118] The experimental results are as follows Fig. 9 As shown, the first round of subcloning was performed on the screened positive well 5C3, as shown in Fig. 9 As shown in Figure A, 41 positive wells were tested, and the figure shows the inhibition rate of 15 strong positive wells. It can be seen that well 3C2 has the highest inhibition rate, and its inhibition rate at 50ng BRO small molecule reaches 65.3%. The second round of subcloning was performed on the screened positive well 3C2, as shown in Figure A. Fig. 9 As shown in Figure B, for 10 6 The inhibition rate of 13 strong positive wells is shown in the figure. It can be seen that well 3H1 has the highest inhibition rate, reaching 81.3% at 25ng BRO small molecule. The first round of subcloning was performed on the screened positive well 3H1, as shown in the figure. Fig. 9 As shown in Figure C, 48 positive wells were tested, and the figure shows the inhibition rate of 13 strongly positive wells. It can be seen that the inhibition rate of 2B10 well is the highest, and its inhibition rate at 5ng BRO small molecule reaches 81.1%.

[0119] (6) Determination of mAb titer and sensitivity

[0120] The ELISA and icELISA methods in Example 2 were used to determine the mAb titer and sensitivity.

[0121] The experimental results are as follows Fig.10 As shown in the figure, the titer of 2B10 cell supernatant is 1:1.28×10 4, its IC 50 The concentration of 2.94 ng / mL showed that it had high affinity and high sensitivity.

[0122] (7) Identification of mAb subtypes

[0123] The isotype of mouse mAb was identified using an antibody isotype identification kit.

[0124] The experimental results are shown in Table 2.

[0125] Table 2 Identification of subtypes of BRO mAbs

[0126]

[0127] As shown in Table 2, the antibody heavy chain subtype of anti-BRO mAb cell 2B10 is IgG1, and the light chain subtype is Kappa.

[0128] (8) Preparation of mouse ascites and determination of titer and sensitivity of anti-BRO mAb

[0129] Six healthy female Balb / c mice that had been fed stably for a week in advance were selected for monoclonal cell injection. One week before the cell injection, 0.5 mL of paraffin oil was injected into the peritoneal cavity of each mouse to promote the formation of ascites. Then, the frozen cell tube was taken out of the liquid nitrogen and the cells were quickly thawed in a 37°C water bath. The thawed cells were centrifuged and washed to remove the cryoprotectant, then resuspended and inoculated into a cell culture bottle. After 80% growth, the culture was expanded. One week later, the mice were injected intraperitoneally to collect the hybridoma cells with good growth conditions. According to 2×10 6 The number of cells per cell was calculated and injected into the abdomen of the mouse using a sterile syringe. The mouse was observed 3 days after injection and ascites was collected from the abdomen of the mouse on days 7-14. If the ascites was less, the ascites could be collected 2-3 times. Finally, the ascites was tested for potency and sensitivity.

[0130] The ELISA and icELISA methods in Example 2 were used to measure the titer and sensitivity of mouse ascites.

[0131] The experimental results are as follows Fig.11 As shown, the titer of mouse ascites can reach 1:1.024×10 5 , IC of mouse ascites 50 It is 2.13ng / mL.

[0132] Example 3: Preparation of anti-BRO single-chain antibody

[0133] 1. Amplification of BRO single-chain antibody gene

[0134] (1) Extraction of RNA from 2B10 cells

[0135] The RNA of the 2B10 cells obtained in Example 2 was extracted using a total RNA extraction kit, and the concentration of the extracted RNA was measured using a micro-nucleic acid protein analyzer. 100 μg of RNA was used for agarose gel electrophoresis experiment to determine its integrity. The extracted total RNA was converted into cDNA by reverse transcription. The reverse transcription system was a 20 μL system: 10 μL total RNA, 4 μL 5× PrimeScript RT Master Mix, 6 μL ddH2O; the reverse transcription process was: 37°C, 15 min, 85°C, 5 s. The electrophoresis diagram of the extracted 2B10 RNA is shown below. Fig.12 shown.

[0136] (2) Amplification of VH and VL fragments

[0137] According to the structural characteristics of mouse IgG, specific primers were designed to amplify the variable region VH and VL fragments of the antibody.

[0138] The primer sequences were: VH for: 5′-TGAGGAGACGGTGACCGTGGTGCC-3′ (SEQ ID NO. 11);

[0139] VH back: 5'-CAGGTSMARCTGCAGSAGTCWGG-3' (SEQ ID NO. 12);

[0140] VL for 1: 5'-CCGTTTTATTTCCAACTTTGTCCC-3' (SEQ ID NO. 13);

[0141] VL for 2: 5'-CCGTTTGATTTCCAGCTTGGTGCC-3' (SEQ ID NO. 14);

[0142] VL for 3: 5'-CCGTTTTATTTCCAGCTTGGTCCC-3' (SEQ ID NO. 15);

[0143] VL for 4: 5'-CCGTTTCAGCTCCAGCTTGGTCCC-3' (SEQ ID NO. 16);

[0144] VL back: 5'-GACATCGAGCTCACTCAGTCTCCA-3' (SEQ ID NO. 17).

[0145] The amplification system was a 50 μL system: PrimeSTAR Max Premix 25 μL, VH for / VL for mix 1.0 μL, VH back / VL back 1.0 μL, cDNA 1.0 μL, and ddH2O was added to 50 μL.

[0146] The amplification conditions were as follows: using cDNA as a template, amplification of VL: 96°C, 10 min; 96°C, 30 s, 56°C, 45 s, 72°C, 1 min, 30 cycles, 72°C, 7 min; amplification of VH: 96°C, 10 min; 96°C, 30 s, 58°C, 45 s, 72°C, 1 min, 30 cycles, 72°C, 7 min.

[0147] The electrophoresis of the amplified product is shown in Fig.13 As shown, the size of the obtained VH gene fragment is about 350 bp, and the size of the VL gene fragment is about 320 bp, which is consistent with the expected size, indicating that the VH and VL gene fragments were successfully amplified, providing a basis for the subsequent construction of ScFv.

[0148] (3) SOE-PCR splicing of ScFv sequences

[0149] The VH and VL gene fragments purified by gel recovery were spliced ​​using Linker, and specific restriction sites VH Back SfiⅠ and VL For NotⅠ were introduced at both ends. The primer sequences of Linker and the two restriction sites are:

[0150] Linker1: 5'-GGCTCTGGCGGTGGCGGATCGGACATTGAGCTCACCCAGTCTCCA-3' (SEQ IDNO.18);

[0151] Linker2: 5'-GACATCGAGCTCACTCAGTCTCCAGAGGCGGTTCAGGCGGAGGT-3' (SEQ IDNO.19);

[0152] VL-NotⅠ: 5'-ATACGGCACCGGCGCACCTgcggccgcCCGTTTTATTTCCAGCCTGGTCCC-3' (SEQ ID NO. 20);

[0153] VH-SfiI: 5'-GTTGTTCCTTTCTATggcccagccggccSCAGGTSMARCTGCAGSAGTCWGG-3' (SEQ ID NO. 21).

[0154] When ligating ScFv, it needs to be divided into two steps. The first step of ligating the PCR reaction system is:

[0155] PrimeSTAR Max Premix 25μL, VH 10μL, VL 10μL, Linker mix 2μL, add ddH2O to 50μL. Reaction conditions: 96℃, 5min, 96℃, 30s, 56℃, 45s, 72℃, 1min; 10 cycles; 72℃, 7min.

[0156] The second-step ligation PCR reaction system is: PrimeSTAR Max Premix 25μL, first-step ligation PCR reaction final solution 10μL, VH-SfiⅠ1μL, VL-NotⅠmix 1μL, add ddH2O to 50μL. The reaction conditions are: 96℃1min; 96℃, 30s, 56℃, 45s, 72℃, 1min, 35 cycles; 72℃, 7min, 4℃ storage. The electrophoresis of the constructed ScFv fragment is shown in the figure below. Fig.14 As shown, a distinct band appeared at about 750 bp, which was consistent with the expected size.

[0157] 2. Construction and identification of ScFv library

[0158] (1) Construction of ScFv-pCANTAB5E recombinant plasmid

[0159] Two restriction endonucleases NotⅠ and SfiⅠ were used to specifically cut the pCANTAB5E vector, enabling it to be effectively spliced ​​with the ScFv fragment. The specific components of the enzyme digestion reaction were: 10×QuickCut Buffer 5μL, Quick CutSfiⅠ1μL, Quick Cut NotⅠ1μL, pCANTAB5E 20μL, add ddH2O to 50μL. The enzyme digestion PCR program was: 37℃, 30min, 50℃, 30min.

[0160] Use recombinase to connect the enzyme linearized pCANTAB5E vector with the ScFv fragment. Splicing PCR program: 37℃, 30min. The connection system is: pCANTAB5E 5μL, ScFv 5μL, Exnase II 2μL, 5×CE II Buffer 4μL, add ddH2O to 20μL. The gel electrophoresis results of double enzyme digestion of pCANTAB-5E are shown in the figure Fig.15 shown.

[0161] (2) Preparation of competent bacteria E. coli TG1

[0162] The E. coli TG1 strain sample was taken out from the -80°C freezer, and inoculated on a 2×YT solid culture medium plate on an ultra-clean workbench for streak operation, and then the plate was placed in a constant temperature environment of 37°C for culturing for 12 to 16 hours.

[0163] After the TG1 E. coli colonies were clearly visible on the plate, a single colony was picked and inoculated into a shake flask containing 20 mL of 2×YT liquid medium. The shake flask was then placed on a constant temperature shaker, set at 37°C and 180 rpm, and continuously shaken for 12 to 16 hours so that the strain could fully grow and reproduce.

[0164] After overnight culture, 500 μL of TG1 bacterial solution was inoculated into 50 mL of new 2×YT liquid medium, maintained at 37°C and 180 rpm shaking conditions, and OD was monitored every 30 min. 600 value to determine the bacterial density.

[0165] When the OD of E.coli TG1 was measured 600 After reaching 0.6, the conical flask containing the bacterial solution was immediately transferred to an ice bath for cooling for 30 minutes, and the conical flask was gently shaken during this period to ensure uniform cooling.

[0166] After the cooling process, carefully transfer the bacterial solution to a sterile 50 mL centrifuge tube. Centrifuge the tube at 4°C and 1000 g for 15 min. Then, carefully pour off the supernatant. Add 50 mL of pre-chilled ddH2O and shake gently to thoroughly resuspend the pellet.

[0167] The supernatant was discarded and the bacterial pellet was resuspended in 25 mL of sterile 10% glycerol solution (mass fraction) precooled to 4°C under the same centrifugation conditions (4°C, 1000 g for 20 min).

[0168] Repeat the above centrifugation and resuspension steps, i.e. centrifuge at 4°C and 1000g for 20 min. This time, discard the supernatant and resuspend the pellet with only 5 mL of pre-cooled 10% glycerol solution.

[0169] Continue the same centrifugation procedure, then carefully remove the supernatant, use a 20 μL pipette to remove the remaining trace supernatant, and add 100 μL of pre-chilled 2×YT medium, and mix gently to fully resuspend the bacteria.

[0170] Dilute the prepared competent bacteria 100 times and take 1u sample to measure OD 600 The concentration was further adjusted using ice-cold 2×YT medium (2.5×10 10 / mL).

[0171] Finally, the treated competent E. coli TG1 bacteria were packaged into 50 μL volumes per tube and stored in a -80°C refrigerator for long-term preservation.

[0172] (3) Transformation and identification of ligation products

[0173] Place the TG1 competent cells prepared in step (2) on ice to maintain a low temperature, and perform electroporation according to the product manual of the electroporator, setting the transformation parameters to 2000 volts and a pulse time of 5 ms. Gently mix 5 μL of the ligation product into 5 μL of the competent bacteria, and after ensuring that the two are evenly mixed, immediately inject the mixture into a pre-cooled to -80°C and sterile electroporation cup, and ensure that the outer wall of the electroporation cup is dry and free of water stains.

[0174] After the electroporation process is completed, 1 mL of 2×YT liquid culture medium preheated at 37°C is quickly added to the electroporation cup. Then, incubate at 37°C with shaking at 200 rpm for 1 hour to promote bacterial recovery. After the incubation is completed, precipitate the bacteria at 5000 rpm for 10 minutes. Carefully remove the supernatant and resuspend the bacterial pellet with 100 μL of 2×YT liquid culture medium. Subsequently, use a spreader to evenly spread the bacterial suspension onto a 2×YT solid culture plate containing antibiotics. At the same time, untransformed TG1 competent bacteria are used as a control. Transfer the coated culture plate to 37°C for overnight culture. After 12-16 hours of culture, observe and count the colonies formed after transformation.

[0175] On the second day, a single colony was selected for expansion and cultured overnight. The following sequences were used for PCR. Primer S1: 5'-CA ACGTGAAAAAATTATTATTCGC-3' (SEQ ID NO.22); S2: 5'-GTAAATGAATTTTCTGTATGAGG-3' (SEQ ID NO.23). PCR system: 2×Taq Master Mix 6.25μL, bacterial solution 1.0μL, S1 0.5μL, S6 0.5μL, add ddH2O to 1.25μL.

[0176] The bacterial samples of the screened positive monoclonal strains were sent to Shanghai Bioengineering Laboratory for DNA sequence analysis. The transformed colonies that grew well on the plate were washed and collected using 2×YT liquid medium, and then the bacterial solution was cultured for 1 hour at 37°C and 180rpm. After the culture was completed, 50% glycerol (mass fraction) was added to the bacterial solution for long-term storage, and the treated bacterial solution was transferred to a -80°C freezing environment for storage.

[0177] (4) Preparation of M13K07 phage

[0178] Bacterial culture and bacteriophage infection:

[0179] A single colony of the TG1 strain was picked from the solid culture medium and inoculated into 10 mL of 2×YT liquid culture medium, and cultured overnight at 37°C with shaking at 160 rpm.

[0180] The next day, 2 mL of the overnight culture was taken out and cultured in 200 mL of 2×YT liquid medium and shaken at 37°C and 180 rpm until the OD reached 0. 600 Close to 0.6.

[0181] Subsequently, 10 μL of the M13K07 helper phage stock stored at -80°C was taken out and added to the bacterial culture medium, which was then placed at 37°C for 30 min to promote phage adsorption. Next, the culture medium was shaken on a shaker at 180 rpm for 30 min to enhance the infection efficiency of the phage.

[0182] Finally, 200 μL of kanamycin was added to the culture solution to screen for successfully transformed bacteria, and the culture was continued overnight at 37°C and 200 rpm.

[0183] (5) Phage precipitation and purification

[0184] Place the prepared phage culture solution in a centrifuge, use 8000rpm, separate for 10 minutes to collect the supernatant. Next, add PEG / NaCl solution to the collected supernatant and mix thoroughly. Then, place the mixed solution in an ice bath and let it stand for 4 hours. Next, centrifuge again at 12000rpm for 20 minutes to collect the precipitate. Discard the supernatant and the precipitate is the phage. Resuspend the precipitate with 1mL of PBS buffer and filter through a 0.45μm filter membrane to remove impurities, then aliquot and store at 4°C.

[0185] (6) Titer determination of helper phage M13K07

[0186] Pre-culture TG1 bacterial solution to OD 600 0.6. Take 1 μL of M13K07 helper phage and measure the titer. Dilute it to 1×10 using PBS. -12concentration. Take out 10μL from each dilution and add it to 100μL of the above-mentioned TG1 bacterial solution. Let it stand at 37°C for 30 minutes to allow the phage to have enough time to infect the bacteria. After that, place it on a shaker and shake it at 180rpm for 30 minutes to speed up the infection. After the infection, use a spreading rod to evenly spread the bacterial solution of each dilution on a 2×YT-K medium plate. Incubate the plate upside down at 37°C overnight. The next day, count the colonies on all plates. Calculate the titer of the M13K07 helper phage based on the number of colonies formed on each plate.

[0187] (7) Construction of anti-BRO phage ScFv library

[0188] Take out 200 μL of the anti-BRO ScFv library at a ratio of 1:100 and inoculate it into 20 mL of 2×YT-A liquid culture medium. Incubate it in an incubator at 37°C and 200 rpm with medium-speed shaking until OD 600 Then, the culture medium was cooled on ice for 15 min to improve the infection efficiency. Then, M13K07 (titer of 10 12 pfu / mL) to ensure that the ratio of bacteria to helper phage was 1:20.

[0189] The culture was shaken at 37°C and 200 rpm. After the culture was completed, the bacterial solution was centrifuged at 4°C and 8000 rpm for 10 minutes to precipitate the bacteria, and the supernatant was discarded. The precipitate was resuspended with 10 mL of 2×YT-AK medium. The resuspended bacterial solution continued to be shaken overnight at 37°C and 200 rpm. The next day, the bacterial solution was centrifuged at 4°C and 10000 rpm for 20 minutes, and the supernatant was collected. 1 / 5 volume of PEG / NaCl solution was added to the supernatant to help phage precipitation. The final precipitate was resuspended with 1 mL of PBS, filtered through a 0.45 nm filter membrane, and stored at 4°C for subsequent screening and enrichment.

[0190] 3. Screening of phage library and obtaining positive single chains

[0191] (1) Phage antibody library screening mainly involves multiple rounds of affinity screening to enrich phage clones that can specifically bind to the target antigen. The screening process includes the following steps:

[0192] Coating stage: BRO-OVA, OVA, BRO-BSA, and BSA were coated in 96-well plates at 4°C overnight at 50 μL / well. Washed with PBST 5 times. The coating concentrations for the four rounds were 50, 25, 12, and 6 μg / mL, respectively.

[0193] Blocking step: Add 200 μL of blocking solution to each 96-well plate and incubate at 37°C for 2 h. Wash three times with PBST solution.

[0194] Add antibody library: add 50 μL PBS buffer to each well, then add 50 μL phage ScFv library, incubate at 37°C for 1 hour. Wash the plate 5 times with PBST solution.

[0195] Elution of positive phages: Pour 200 μL (pH 2.2) of elution buffer into each well, shake on a constant temperature shaker for 10 minutes, and then immediately add 50 μL (pH 9.2) of neutralization buffer to obtain the first round of elution buffer.

[0196] Titer determination: Take 1 μL of the eluate for titer determination and process it using the same determination method as M13KO7. The next day, accurately count the colonies formed on the plate and calculate the actual number of recovered phages.

[0197] Phage amplification: Take 500 μL of the eluted material from the previous step and add it to 20 mL of TG1 bacterial solution that has been cultured to the logarithmic growth phase. Then, add 20 μL of ampicillin to the mixture. Let the bacterial solution stand at room temperature for 30 minutes, then add 2×10 10 pfu of helper phage M13K07 and let it stand again for 30 minutes. After the standing is completed, the bacterial solution is shaken at 37°C at 180rpm for 30 minutes. Next, use a centrifuge to centrifuge at 8000rpm for 10 minutes to precipitate the phage. After the centrifugation is completed, the supernatant is carefully discarded, and then the precipitate is resuspended with 30mL of 2×YT-AK. The resuspended bacterial culture solution is cultured overnight at 37°C at 180rpm.

[0198] Precipitating phages: After completing the amplification of the phages, the phages are concentrated using the PEG / NaCl precipitation method. This marks the completion of the first round of screening enrichment. Subsequently, a total of four rounds of screening will be carried out to further purify and screen the phages. The pressure of screening increases with each round to improve the efficiency of the screening and ensure that the screened phages have higher specificity and affinity.

[0199] The results of four rounds of screening and enrichment are shown in Table 3.

[0200] Table 3 Four rounds of screening and enrichment of BRO phage antibody library

[0201]

[0202] As shown in Table 3, after the fourth round of screening, the recovery rate of phages increased by 190 times compared with the first round. This result shows that through the continuous screening process, specific phages were effectively enriched and the screening strategy achieved significant success. After such a screening process, the phage library finally obtained contained a large number of ScFvs with high specificity and high affinity for BRO, providing a material basis for subsequent research.

[0203] (2) Identification of ScFv-positive bacteria by PCR

[0204] The eluted products obtained from the fourth round of screening were diluted in gradients and used to infect TG1 bacterial liquid in the logarithmic growth phase. After standing at 37°C for 30 minutes, they were placed in a shaker at 180 rpm and continued to be shaken for 30 minutes. Subsequently, the mixed solution was spread on a 2×YT-A solid plate and cultured overnight at 37°C.

[0205] The next day, 25 representative colonies were selected from the monoclonal colonies that had been formed, and each colony was inoculated into 1 mL of 2×YT-A liquid culture medium and cultured overnight for further expansion.

[0206] From the above overnight cultured bacterial solution, 5 μL was taken as a PCR reaction template for bacterial solution PCR operation. Positive bacterial solution samples were sent to Shanghai Biotechnology for sequencing analysis.

[0207] The experimental results are as follows Fig.16 As shown, the results showed that 18 of the 20 single colonies could amplify bands, with a positive rate of 90%. The positive colonies were sequenced and the insertion fragment of about 750bp was confirmed. By Blast comparison analysis, 8 different ScFv gene sequences were found in the library. The library capacity diversity was 44.4%, indicating that the antibody library had good diversity.

[0208] (3) Amplification and titer determination of positive phage ScFv

[0209] Amplification and titer determination of the same phage M13KO7.

[0210] (4) Phage-ELISA of BRO-positive phage ScFv

[0211] First, select 50 μL of the phage sample that has been sequenced and confirmed to be positive as the primary antibody, add it to a 96-well ELISA plate pre-coated with 50 μg / mL BRO-OVA, and incubate at 37°C for 2 hours. After incubation, wash 5 times with PBST solution to remove unbound primary antibody. Next, add 50 μL of HRP-labeled anti-M13 antibody at a concentration of 0.4 μg / mL to each well as a secondary antibody, and continue to incubate at 37°C for 1 hour. After incubation, wash 5 times with PBST solution. Subsequently, add 50 μL of TMB colorimetric solution to each well, and color develop at 37°C for 10 minutes. After color development, quickly add 50 μL of stop solution to the well. Finally, use an ELISA instrument to measure the OD of each well. 450 Value determination.

[0212] The experimental results are as follows Fig.17 As shown, OD was measured 450 Finally, the P / N value was calculated to measure the binding strength between the ScFv on the phage surface and the antigen. P / N>2.1 indicated a high binding ability. The results showed that the P / N of 4 monoclonal phages exceeded 2.1, indicating that the ScFv they carried had a high binding strength to the target antigen, among which the P / N value of No. 12 was 7.46.

[0213] Phagemids with a P / N value of ≥2.1 were selected, and a total of 4 strains were submitted to Bioengineering for sequencing. After analysis, the sequence results of phagemid No. 12 were consistent with the characteristics of ScFv, and the sequencing results were:

[0214] The sequence of the heavy chain variable region of the single-chain antibody is as follows:

[0215] MAQVQLQESGPELKKPGETVKISCKTSGNTFTDYGMDWVKQAPGKGLKWMGRINTKTGVPT YAEEFKGRFAFSLETSASTAYLQINNLRNEDMASYFCASPIYFYSGWYFDVWGQGTTVTV(SEQ ID NO.1);

[0216] The sequence of the light chain variable region is as follows:

[0217] DIELTQSPALMAASPGEKVTITCSVSSSISSSYLHWYQQKSGISPKPWIYGTSNLASGVPTRFSGSGSGTSYSLTIRSMEAEDAATYYCQQWSRSPPRSEGGPSWS(SEQ ID NO.2);

[0218] The amino acid sequence of the connecting peptide is as follows: SSGGGGSGGGGSGGGGS (SEQ ID NO. 5).

[0219] IV. Expression and identification of anti-BRO single-chain antibody

[0220] (1) Preparation of anti-BRO phage ScFv

[0221] Cultivate positive bacteria: inoculate the positive bacteria into 2×YT-A liquid culture medium at a ratio of 1:100, and culture at 37°C and 180 rpm with shaking until it reaches the logarithmic growth phase, which usually takes 2 hours and 20 minutes.

[0222] Phage infection: helper phage M13K07 (2×10 10 pfu / mL) was added to the bacterial culture and incubated at 37°C for 30 min. It was then placed in a shaker at 37°C and 180 rpm for 30 min.

[0223] Phage amplification: The bacterial culture was centrifuged at 8000 rpm for 10 min at 4 °C, the supernatant was discarded, the pellet was resuspended in 2×YT-AK medium, and then incubated overnight at 37 °C with shaking at 180 rpm.

[0224] Phage harvesting and purification: The bacterial culture was centrifuged at 10,000 rpm for 15 min at 4 °C to precipitate the bacteria. The supernatant was collected and mixed with 1 / 5 volume of PEG / NaCl solution for phage precipitation. After thorough mixing, the mixture was cooled on ice for 4 h and then centrifuged at 10,000 rpm for 20 min at 4 °C. The supernatant was discarded and the phage pellet was resuspended in 1 mL PBS. The suspension was then filtered through a 0.45 μm filter to remove bacterial debris and obtain the phage ScFv solution, which was stored at 4 °C until further use.

[0225] (2) Soluble expression of anti-BRO phage ScFv

[0226] Phage inoculation: 2 μL of the screened BRO positive phage was added to 100 μL of the culture medium of Escherichia coli HB2151 in the logarithmic growth phase for phage inoculation.

[0227] Colony isolation and culture: The mixed solution was cultured in a constant temperature box for 30 minutes, then transferred to a constant temperature shaker and cultured at a speed of 180 rpm / min for 30 minutes. The treated mixed bacterial solution was evenly spread on a 2×YT-A culture plate and cultured overnight at 37°C to achieve colony isolation and growth.

[0228] Colony proliferation and culture: The next day, a single colony was selected from the plate and inoculated into 10 mL of 2×YT-A liquid medium, maintained at 37°C, 180 rpm / min, and cultured overnight. On the third day, the overnight culture was inoculated into 200 mL of 2×YT-A medium at a ratio of 1:100, and cultured at 30°C, 180 rpm / min until it entered the logarithmic growth phase.

[0229] Induced expression and sample collection: When the bacterial solution enters the logarithmic growth phase, IPTG is added for induction to a final concentration of 1mmol / L (equivalent to 476μL). The culture temperature is set at 30°C and the induction is continued for 10h. After the induction is completed, the bacterial solution samples are collected, and the E. coli HB2151 bacterial solution and the HB2151 strain carrying the pCANTAB5E vector are used as controls.

[0230] (3) Acquisition of BRO-ScFv in the periplasm

[0231] After inducing expression, the bacterial culture was centrifuged at 5,000 rpm for 20 min to separate the supernatant and the precipitate. The supernatant was filtered through a 0.45 μm filter and stored at 4 ° C for the next identification analysis. For the precipitate, it was resuspended in 1 mL of ice-cold 1× TES solution. After vortexing the mixture, the suspension was incubated on ice for 30 min. Subsequently, the suspension was centrifuged at 11,000 rpm for 15 min at 4 ° C. After centrifugation, the supernatant of soluble antibodies secreted into the periplasmic cavity was collected. Finally, the protein expression in the obtained supernatant was analyzed using SDS-PAGE and Western Blotting methods.

[0232] Western Blotting results are as follows Fig.18 As shown, the protein bands on the transferred NC membrane were clearly visible, proving the presence of the target protein.

[0233] (4) BRO-ScFv biological activity detection

[0234] ① Indirect ELISA method is used to detect soluble BRO-ScFv recombinant antibody. The operation steps are as follows:

[0235] Antigen coating: Add 3 μg / mL BRO-OVA antigen solution to the ELISA plate, 50 μL per well. Then, place the ELISA plate at 4°C overnight. The next day, wash 5 times with PBST solution, 5 minutes each time.

[0236] Blocking: Add 200 μL of PBST solution containing 5% skim milk powder to each well of the ELISA plate coated with antigen. The blocking process is carried out at 37°C for 2 hours. Wash 5 times with PBST solution, each wash for 5 minutes.

[0237] Sample incubation: Add 50 μL of the soluble BRO-ScFv recombinant antibody solution to each well of the ELISA plate, with an initial dilution of 1:5. At the same time, set the E. coli HB2151 empty strain as a negative control. Incubate the ELISA plate at 37°C for 1 hour to allow the antibody to fully react with the antigen. After incubation, wash 5 times with PBST, 5 minutes each time.

[0238] Secondary antibody incubation: Add 50 μL of HRP-labeled anti-E-tag antibody (dilution ratio 1:5000) to each well and continue incubation at 37°C for 30 min. After incubation, wash 5 times with PBST solution, 5 min each time.

[0239] Color development reaction: Then, add 50 μL of TMB color development solution to each well and react for 7 min at room temperature in the dark. After the reaction is completed, add 50 μL of 2M H2SO4 stop solution to stop the color development reaction.

[0240] Absorbance measurement and result analysis: Use an ELISA reader to measure the absorbance of each well at a wavelength of 450nm. Take the reading of the blank control well as the zero point, and record the OD of the sample well (P) and the negative control well (N). 450 By comparing the OD values ​​of the sample wells and the negative control wells, the P / N ratio is calculated. If P / N ≥ 2.1, it can be judged as a positive reaction, indicating that the soluble BRO-ScFv recombinant antibody has specific binding to the BRO-OVA antigen. If the P / N ratio is lower than the threshold, it is judged as a negative reaction.

[0241] ②Sensitivity detection of soluble BRO-ScFv

[0242] To analyze the affinity of soluble BRO-ScFv, follow these steps:

[0243] Coating antigen: Add 3 μg / mL BRO-OVA to each well of the ELISA plate, with a volume of 50 μL per well. Place the ELISA plate at 4°C overnight. Then, wash 5 times with PBST solution, 5 minutes each time.

[0244] Blocking: Add 200 μL of PBST solution containing 5% skim milk powder to each well. Place in a 37°C incubator for 2 hours. After blocking, wash 5 times with PBST solution, 5 minutes each time.

[0245] Competition reaction: Add 50 μL of periplasmic extract to each well, and then immediately add 50 μL of BRO standards of different concentrations (1 ng / mL, 2.5 ng / mL, 5 ng / mL, 10 ng / mL, 25 ng / mL, 50 ng / mL, 100 ng / mL, 250 ng / mL). Among them, the well without BRO standard was used as a positive control. It was placed in a constant temperature box at 37°C for 1 hour. After the incubation, PBST solution was used to wash 5 times, each wash for 5 minutes.

[0246] Incubate with secondary antibody: Add 50 μL of HRP-labeled anti-E-tag antibody solution diluted 1:5000 to each well. Return the ELISA plate to the 37°C incubator and continue incubation for 30 minutes. After incubation, wash 5 times with PBST solution, 5 minutes each time.

[0247] Color development: Add 50 μL of TMB single-component color development solution to each well and react for 10 minutes at room temperature in the dark to allow the color development reaction to proceed fully. Subsequently, add stop solution (2M H2SO4) to terminate the reaction, with 50 μL added to each well.

[0248] Read the data: Use a microplate reader to read the OD 450 The absorbance of each well was detected at the wavelength and zeroed according to the absorbance of the blank control well to eliminate background interference.

[0249] Calculation: Use Origin 2021 software and the Logistics5 function equation to fit the obtained data. Draw a standard curve with the logarithm of the standard concentration as the horizontal axis and the absorbance value B / B0 (the ratio of the absorbance value of the sample well to the absorbance value of the blank well) as the vertical axis. Calculate the IC through the fitted curve. 50 , which reflects the sensitivity level of soluble BRO-ScFv binding to BRO-OVA.

[0250] The experimental results are as follows Fig.19 As shown, the P / N of BRO-ScFv was ≥ 2.1, which was judged as positive, and the titer was about 1:64. The calculated IC 50 The value is 13.16ng / mL.

[0251] (5) Specificity analysis of soluble BRO-ScFv

[0252] CL, CIB, SAL, RAC, TBL, ZIL and CIM were selected as competitive small molecules for specificity analysis experiments to determine whether cross-reactions would occur and calculate IC 50 value, and use the formula CR% = IC 50 (Standard product) / IC 50(structural analogues)×100%, and calculate the corresponding cross-reaction rate.

[0253] The experimental results are shown in Table 4.

[0254] Table 4 Cross-reaction rate between BRO-ScFv and structural analogs

[0255]

[0256] The results showed that the cross-reaction rates of BRO-ScFv antibody with CL and CIB were 31.1% and 26.25%, respectively, and the cross-reaction rates with other small molecules were less than 0.1%.

[0257] Example 4: Synthesis and identification of ZIL complete antigen

[0258] 1. ZIL molecular modification

[0259] (1) Before synthesizing the complete ZIL antigen, the ZIL must be molecularly modified to introduce the side chain -COOH.

[0260] 100 mg of ZIL-HCL was weighed on a ppm analytical balance and added to 10 mL of 1 mol / L NaOH solution. The mixture was extracted with 5 mL of ethyl acetate for 5 times to obtain ZIL free base. The ethyl acetate layer was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated using a rotary evaporator.

[0261] 5 mL of acetone, ethyl 4-bromobutyrate and potassium carbonate were added to the product and refluxed. The potassium carbonate was removed by filtration and the acetone was dried by a rotary evaporator.

[0262] Reflux with 10 mL of 66% (v / v) ethanol and 34% KOH (v / v) aqueous solution at 80°C for 3 h, turn off the heater and react overnight at room temperature. Dry the ethanol with a rotary evaporator, adjust the pH to about 3.0 with 2 mol HCL, extract with ethyl acetate, and retain the ethyl acetate phase and the aqueous phase separately.

[0263] (2) Coupling of ZIL with carrier protein

[0264] The ZIL was coupled to the carrier protein BSA / OVA according to the EDC / NHS method. The specific process is as follows:

[0265] The obtained product was dissolved in MES (pH 5.0) buffer solution, 1 mL of DMF was added and mixed, 10 mg of EDC and 6 mg of NHS were added, and the mixture was stirred in an ice-water bath for 2 h, which was recorded as liquid A, and the solution was divided into two parts; 12 mg of BSA was weighed and dissolved in 1 mL of sodium borate buffer solution, and the mixture was in a water bath at 40 ° C for 30 min. Liquid A was added dropwise under stirring at room temperature, and stirred at room temperature overnight; 10 mg of OVA was weighed and dissolved in 1 mL of sodium borate buffer solution, and the mixture was in a water bath at 30 ° C for 30 min. The activated liquid A was added dropwise under stirring at room temperature, and stirred at room temperature overnight; the reaction product was collected and dialyzed with 0.01 mol / L PBS as the dialysis buffer. The dialyzate was changed 3 times a day. Centrifuged at 5000 r / min for 5 min. The collected products were labeled as ZIL-BSA and ZIL-OVA and placed in a -20 ° C refrigerator.

[0266] (3) Complete antigen concentration identification, SDS-PAGE identification and UV full wavelength identification

[0267] The identification method is the same as in Example 1, and the experimental results are as follows Figure 20-22 shown.

[0268] The linear regression equation is y = 2.506x + 0.5623, R 2 =0.99, which meets the calculation requirements. Substituting the OD values ​​of the corresponding dilution concentrations of the complete antigen ZIL-BSA and ZIL-OVA into the standard curve, it was calculated that the protein concentration of the immune antigen ZIL-BSA was 4.8 mg / mL, and the protein concentration of the coated original ZIL-OVA was 0.71 mg / mL.

[0269] like Fig. 20 and Fig.21 As shown, it can be observed that the migration rates of the coupled complete antigens ZIL-BSA and ZIL-OVA are both lower than those of the carrier proteins BSA and OVA, indicating that the molecular weight of the ZIL-BSA and ZIL-OVA obtained after coupling increases, indicating that the coupling of ZIL and the carrier protein BSA / OV is successful.

[0270] like Fig. 22 As shown, the maximum absorption peak wavelength of the coupling product and the maximum absorption peak wavelength of the carrier protein were shifted, which can prove that the coupling of ZIL and the carrier protein was successful.

[0271] 2. Animal Immunization

[0272] The experimental method is the same as in Example 1, and the experimental results are as follows Fig.23 As shown in Figure 2, all three BALB / c mice immunized with the immunogen ZIL-BSA produced anti-ZIL antibodies, as measured by OD 450 nm>0.3, P / N>2.1 as the judgment standard, relative to the negative mouse serum, the polyclonal antibody titer of the immunized mice reached 1:1.128×10 4 . This indicates that the prepared complete antigen ZIL-BSA\OVA can be used in subsequent experiments.

[0273] Example 5: Screening and identification of hybridoma cell lines

[0274] (1) Cell fusion and screening of positive hybridoma cells were performed according to the method in Example 2.

[0275] The experimental results are shown in Table 5.

[0276] Table 5 Results of cell fusion initial test inhibition rate

[0277]

[0278] As shown in Table 4, OD 450nm The wells with a value greater than 1.0 were determined as positive wells. After fusion, 26 positive wells were obtained in the initial screening. The positive well 5E7 with the highest inhibition rate of 57.0% at 100 ng / mL ZIL was selected for subcloning to prepare single-chain antibodies.

[0279] (2) Perform limiting dilution of positive cell wells according to the method in Example 2

[0280] After three subcloning dilutions, the positive well 5E7-A9 was obtained and its IC 50 The value was 1.75ng / mL. The hybridoma cell 5E7-A9 was finally screened and deposited in Guangdong Microbiological Culture Collection Center, Building 59, No. 100 Xianlie Middle Road, Guangzhou, on August 9, 2023, with the deposit number: GDMCC No: 63432.

[0281] (3) Stability determination of hybridoma cells

[0282] The hybridoma cells 5E7-A9 were taken out and frozen and revived for 4 times. When the cells were in the best growth state, the cell supernatant was collected for titer detection. The results are shown in Table 6. The titer of the cell supernatant was stable at 1:3.2×10 3 This indicates that the hybridoma cell 5E7-A9 has good growth in vitro and can stably secrete ZILmAb.

[0283] Table 6 Determination of 5E7-A9 cell supernatant titer

[0284]

[0285] Example 6: Preparation of single-chain antibodies

[0286] 1. Preparation of anti-ZIL single-chain antibody

[0287] The hybridoma cell 5E7-A9 was injected into the mouse peritoneal cavity to prepare the anti-ZIL single-chain antibody. The specific process is as follows:

[0288] (1) 1 week in advance, 500 μL of sterilized liquid paraffin was intraperitoneally injected into 10 BALB / c mice. Before injection, the liquid paraffin was sterilized by high pressure and filtered with a 0.22 μm filter membrane in a clean bench to remove impurities;

[0289] (2) Monoclonal hybridoma cells were collected, washed twice with PBS, and the cell density was adjusted by cell counting. 6 The cells were injected into the peritoneal cavity of mice.

[0290] (3) After about 7 to 10 days, the abdominal cavity of the mouse swells and becomes larger. The ascites can be collected on the 10th day, centrifuged at 3500 r / min for 5 minutes to remove impurities, and stored at -80°C for later use. The titer of the mouse ascites is then tested by ELISA. The test results are shown in Fig.24 ICELISA was used to detect IC in mouse ascites 50 Value, test results see Fig.25 shown.

[0291] like Fig.24 and Fig.25 As shown, the titer of mouse ascites can reach 1:4.096×10 5 , mouse ascites IC 50 The results showed that hybridoma cell 5E7-A9 can stably secrete ZIL mAb, and the secreted single-chain antibody has high titer and sensitivity, which can be used for subsequent experiments.

[0292] 2. Construction and identification of ZIL single-chain antibody

[0293] The construction and screening methods of ZIL single-chain antibodies were the same as those in Example 3. After screening, ZIL-phage-ScFv-5 positive phages were obtained. The obtained anti-ZIL single-chain antibodies were sent to Shanghai Biotechnology for sequencing. The sequence of the heavy chain variable region of the single-chain antibody was as follows:

[0294] EVKLQQSGGGLVKPGGSIKISCAASGFAFSSYGVSWVRQTPEKRLEWVAYISGGGGTTYYADTV RGRFTISRDNAKNTLYLQMNSLKSEDTAMYYCSRHEARRGYALDYWGQGTTVTVSS(SEQ ID NO.6);

[0295] The light chain variable region sequence is as follows:

[0296] DIELTQSPSSMYASLGERVTITCKASQDIKSYLSWYQQKPWKSPKTLIYYATSLADGVPSRFSGS GSGQDYSLTISSLESDDTATYYCLQHGESPLTFGAGTKLELKR (SEQ ID NO. 7).

[0297] The connecting peptide sequence is as follows: GGGGSGGGGSGGGGS (SEQ ID NO. 10).

[0298] The ZIL-phage-ScFv-5 single-chain antibody was expressed and identified by referring to the method in Example 3, a recombinant expression vector was constructed, and the titer, sensitivity and specificity of the obtained ZIL single-chain antibody were identified.

[0299] The experimental results are shown in Tables 7, 8 and Fig.26 shown.

[0300] Table 7 Determination of ZIL single chain antibody protein titer

[0301]

[0302] Table 8 Specificity identification of ZIL single chain antibody

[0303]

[0304] As shown in Table 7, the titer of the ZIL single-chain antibody protein is 1:16, indicating that the ZIL single-chain antibody protein can recognize each other with ZIL-BSA. The dilution of 1:6 is used as the optimal dilution of ScFv in indirect ELISA, and the standard curve is as follows Fig.26 As shown, after calculation, its IC 50 According to the specific identification results, ZIL single-chain antibody basically does not recognize other structural analogs and has excellent specificity.

[0305] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An anti-β-agonist single-chain antibody, characterized in that The β-agonist is bromobuterol, and the anti-bromobuterol single-chain antibody is composed of a heavy chain variable region, a connecting peptide and a light chain variable region. The connecting peptide is located between the heavy chain variable region and the light chain variable region. The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

2.

2. The anti-β-agonist single-chain antibody according to claim 1, characterized in that The nucleotide sequence encoding the heavy chain variable region of the anti-bromobuterol single-chain antibody is shown in SEQ ID NO.3, and the nucleotide sequence encoding the light chain variable region is shown in SEQ ID NO.

4.

3. The anti-β-agonist single-chain antibody according to claim 1, characterized in that The amino acid sequence of the connecting peptide is shown in SEQ ID NO.

5.

4. The anti-β-agonist single-chain antibody according to claim 1, characterized in that The β-agonist is zilpaterol, and the anti-zilpaterol single-chain antibody is composed of a heavy chain variable region, a connecting peptide and a light chain variable region. The connecting peptide is located between the heavy chain variable region and the light chain variable region. The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.6, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

7.

5. The anti-β-agonist single-chain antibody according to claim 4, characterized in that The nucleotide sequence encoding the heavy chain variable region of the anti-zilpaterol single-chain antibody is shown in SEQ ID NO.8, and the nucleotide sequence encoding the light chain variable region is shown in SEQ ID NO.

9.

6. The anti-β-agonist single-chain antibody according to claim 4, characterized in that The amino acid sequence of the connecting peptide is shown in SEQ ID NO.

10.

7. An expression vector, bacteriophage or recombinant bacterium, characterized in that: Includes all the nucleotides described in claim 2 or 5.

8. A monoclonal cell line, characterized in that: Includes all the nucleotides described in claim 2 or 5.

9. A kit for detecting beta-stimulants, characterized in that: A single-chain antibody against β-agonist comprising any one of claims 1-6.

10. Use of the anti-β-agonist single-chain antibody according to any one of claims 1 to 6 or the kit for detecting β-agonists according to claim 9 in detecting β-agonists.

Citation Information

Patent Citations

  • Single-chain antibody and application thereof in detecting beta-stimulant

    CN102653561A